The initial investment of 3 million Euros is the first branch of BI X outside Germany.
Today, innovation-driven German pharmaceutical company Boehringer Ingelheim announces that ‘s digital innovation laboratory BI X has officially decided to set up its first overseas branch in Shanghai , I hope to provide customized digital medical solutions for Chinese patients and customers . So far, Boehringer Ingelheim has also become one of the first foreign-funded pharmaceutical companies to set up special digital innovation branches in China.
It is reported that the branch office of BI X Lab in Shanghai will be formally completed in July this year, and will work closely with Boehringer Ingelheim China headquarters and German BIX headquarters. The initial investment of the project is 3 million Euros. . In addition, BI X Labs will also recruit 20 innovative talents with deep experience in digital healthcare to provide innovative solutions for Chinese patients.
BI X’s office in Ingelheim, Germany
In response, Michael Schmelmer, member of Boehringer Ingelheim’s executive board and head of global finance, said, Digital innovation in China’s healthcare sector is booming, and it is leading the wave in high technology. Therefore, BI X decided to open its first overseas branch in Shanghai, which will allow the company to be closer to Chinese patients and customers, develop more disruptive and innovative solutions and products, and make fuller use of digital resources.
The first two letters of the BIX name are derived from the acronym of the company’s English name Boehringer Ingelheim, and X stands for infinite exploration of the unknown. I learned that the Boehringer Ingelheim Digital Lab BI X was established in 2017, and aims to make full use of innovative technologies in the digital field to accelerate the development of treatment methods.
BI X Lab is a master and data scientist of Scrum, an agile programming platform., Engineers and user experience designers, as well as senior medical and health experts, the “strongest brains” work together to complete the process of digital medical applications from initial attempts to application verification in a short time.
This year coincides with the 25th anniversary of Boehringer Ingelheim’s entry into the Chinese market. Gao Qifei, President and CEO of Boehringer Ingelheim Greater China, said that China has been and continues to be one of Boehringer Ingelheim’s most important markets; in addition, this is also the birthplace and center of global digital health innovation, so the company will continue Investing in the Chinese market will further promote the development and growth of the Chinese market.
Boehringer Ingelheim was founded in 1885 and is still a family business and one of the top 20 pharmaceutical companies in the world. It is involved in human pharmaceuticals, animal health, biopharmaceutical contract production, and health innovation (BI X Labs is one of them. A highlight) four major business areas.
Boehringer Ingelheim officially entered the Chinese market in 1994. The total investment in China currently exceeds 300 million Euros. The company’s management headquarters are located in Shanghai and its business covers the whole country. In 2018, Boehringer Ingelheim achieved net sales of approximately 17.5 billion euros; R & D expenditures were approximately 3.2 billion euros, equivalent to 18.1% of net sales.